TY - JOUR
T1 - Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA Vector
AU - Andrade, Luis A.F.
AU - Versiani, Alice F.
AU - Barbosa-Stancioli, Edel F.
AU - dos Reis, Jenner K.P.
AU - dos Reis, Jordana Grazziela A.C.
AU - da Fonseca, Flavio G.
N1 - Funding Information:
This research was funded by CNPq and FAPEMIG through the National Institutes of Science and Technology of Vaccines (INCTV).
Funding Information:
We thank CNPQ and CAPES for the financial support; the Microbiology Department of Federal University of Minas Gerais for providing facilities; and the Retroviruses Laboratory-Retrolab Federal University of Minas Gerais for providing FIV p24 protein and western blot protocols. We are indebted to Fabiana Magalhães Coelho for the FIV-positive samples which were of great importance for the execution of this work.
Publisher Copyright:
© 2022 by the authors.
PY - 2022/10
Y1 - 2022/10
N2 - The feline immunodeficiency virus (FIV) is a retrovirus with global impact and distribution, affecting both domestic and wild cats. This virus can cause severe and progressive immunosuppression culminating in the death of felids. Since the discovery of FIV, only one vaccine has been commercially available. This vaccine has proven efficiency against FIV subtypes A and D, whereas subtype B (FIV-B), found in multiple continents, is not currently preventable by vaccination. We, therefore, developed and evaluated a vaccine prototype against FIV-B using the recombinant viral vector modified vaccinia virus Ankara (MVA) expressing the variable region V1–V3 of the FIV-B envelope protein. We conducted preclinical tests in immunized mice (C57BL/6) using a prime-boost protocol with a 21 day interval and evaluated cellular and humoral responses as well the vaccine viability after lyophilization and storage. The animals immunized with the recombinant MVA/FIV virus developed specific splenocyte proliferation when stimulated with designed peptides. We also detected cellular and humoral immunity activation with IFN-y and antibody production. The data obtained in this study support further development of this immunogen and testing in cats.
AB - The feline immunodeficiency virus (FIV) is a retrovirus with global impact and distribution, affecting both domestic and wild cats. This virus can cause severe and progressive immunosuppression culminating in the death of felids. Since the discovery of FIV, only one vaccine has been commercially available. This vaccine has proven efficiency against FIV subtypes A and D, whereas subtype B (FIV-B), found in multiple continents, is not currently preventable by vaccination. We, therefore, developed and evaluated a vaccine prototype against FIV-B using the recombinant viral vector modified vaccinia virus Ankara (MVA) expressing the variable region V1–V3 of the FIV-B envelope protein. We conducted preclinical tests in immunized mice (C57BL/6) using a prime-boost protocol with a 21 day interval and evaluated cellular and humoral responses as well the vaccine viability after lyophilization and storage. The animals immunized with the recombinant MVA/FIV virus developed specific splenocyte proliferation when stimulated with designed peptides. We also detected cellular and humoral immunity activation with IFN-y and antibody production. The data obtained in this study support further development of this immunogen and testing in cats.
KW - feline immunodeficiency virus
KW - modified vaccinia virus Ankara
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85140883582&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140883582&partnerID=8YFLogxK
U2 - 10.3390/vaccines10101717
DO - 10.3390/vaccines10101717
M3 - Article
AN - SCOPUS:85140883582
VL - 10
JO - Vaccines
JF - Vaccines
SN - 2076-393X
IS - 10
M1 - 1717
ER -